Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

Journal of Neurochemistry

Volumn 105, Issue 5, 2008, Pages 1970-1978

  Zhu, Wen ^a,b   Xie, Wenjie ^a   Pan, Tianhong ^a   Jankovic, Joseph ^a   Li, Jun ^a   Youdim, Moussa B H ^c   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Lactacystin; Neuroprotection; Neurorestoration; Rasagiline; Selegiline; Ubiquitin proteasome system

Indexed keywords

LACTACYSTIN; PROTEASOME INHIBITOR; RASAGILINE; SELEGILINE;

ARTICLE; CELL LOSS; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL;

ACETYLCYSTEINE; ANIMALS; DOPAMINE; INDANS; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; SELEGILINE;

ANIMALIA; MUS;

EID: 43549107707     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05330.x     Document Type: Article

References (46)

1. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M. B., Tsujimoto Y. Naoi M. (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82 (4 913 923.
2. Am O. B., Amit T. Youdim M. B. (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355 (3 169 172.
3. Bar-Am O., Amit T. Youdim M. B. (2007). Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 103, 500 508.
4. Bayes M., Rabasseda X. Prous J. R. (2006) Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 28 (9 657 678.
5. Blandini F. (2005) Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? CNS Drug Rev. 11 (2 183 194.
6. Chen J. J. Swope D. M. (2006) Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 45 (8 878 894.
7. Ciechanover A., Orian A. Schwartz A. L. (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22 (5 442 451.
8. Ding Q., Dimayuga E. Keller J. N. (2006) Proteasome regulation of oxidative stress in aging and age-related diseases of the CNS. Antioxid. Redox Signal. 8 (1-2 163 172.
9. Finberg J. P., Lamensdorf I., Weinstock M., Schwartz M. Youdim M. B. (1999) Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv. Neurol. 80, 495 499.
10. Fornai F., Lenzi P., Gesi M. et al. (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23 (26 8955 8966.
11. Fornai F., Lenzi P., Gesi M. et al. (2004) Similarities between methamphetamine toxicity and proteasome inhibition. Ann. NY Acad. Sci. 1025, 162 170.
12. Fornai F., Lazzeri G., Bandettini Di Poggio A., Soldani P., de Blasi A., Nicoletti F., Ruggieri S. Paparelli A. (2006) Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity. Ann. NY Acad. Sci. 1074, 84 89.
13. Gassen M., Lamensdorf I., Armony T., Finberg J. P. Youdim M. B. (2003) Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J. Neural. Transm. 110 (2 171 182.
14. Gesi M., Santinami A., Ruffoli R., Conti G. Fornai F. (2001) Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). Pharmacol. Toxicol. 89 (5 217 224.
15. Glaser J. R. Glaser E. M. (2000) Stereology, morphometry, and mapping: the whole is greater than the sum of its parts. J. Chem. Neuroanat. 20, 115 126.
16. Grunblatt E., Mandel S., Jacob-Hirsch J. et al. (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm. 111 (12 1543 1573.
17. Lazzeri G., Lenzi P., Gesi M., Ferrucci M., Fulceri F., Ruggieri S., Bruno V. Fornai F. (2006) In PC12 cells neurotoxicity induced by methamphetamine is related to proteasome inhibition. Ann. NY Acad. Sci. 1074, 174 177.
18. +)-induced apoptosis independent of MAO-B inhibition. Neurosci. Lett. 224 (3 197 200.
19. Lee M., Hyun D. H., Marshall K. A., Ellerby L. M., Bredesen D. E., Jenner P. Halliwell B. (2001) Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. Free Radic. Biol. Med. 31 (12 1550 1559.
20. McNaught K. S. Olanow C. W. (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol. Aging 27 (4 530 545.
21. McNaught K. S., Perl D. P., Brownell A. L. Olanow C. W. (2003) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (1 149 162.
22. Muralikrishnan D., Samantaray S. Mohanakumar K. P. (2003) D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse 50 (1 7 13.
23. Nagatsu T. Sawada M. (2006) Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J. Neural Transm. Suppl. 71, 53 65.
24. Nair V. D., McNaught K. S., Gonzalez-Maeso J., Sealfon S. C. Olanow C. W. (2006) p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281 (51 39550 39560.
25. Olanow C. W. (2006) Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology 66 (10 Suppl. 4 S69 S79.
26. Palhagen S., Heinonen E., Hagglund J., Kaugesaar T., Maki-Ikola O., Palm R. Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (8 1200 1206.
27. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61 (4 561 566.
28. Rideout H. J., Lang-Rollin I. C., Savalle M. Stefanis L. (2005) Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem. 93 (5 1304 1313.
29. Sagi Y., Mandel S., Amit T. Youdim M. B. (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25 (1 35 44.
30. Shoulson I. (1998) DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann. Neurol. 44 (3 Suppl. 1 S160 S166.
31. Siderowf A. Stern M. (2003) Update on Parkinson disease. Ann. Intern. Med. 138 (8 651 658.
32. Tabakman R., Lecht S. Lazarovici P. (2004) Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays 26 (1 80 90.
33. Tatton W. G., Chalmers-Redman R. M., Ju W. J., Mammen M., Carlile G. W., Pong A. W. Tatton N. A. (2002) Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301 (2 753 764.
34. Tipton K. F., Boyce S., O'Sullivan J., Davey G. P. Healy J. (2004) Monoamine oxidases: certainties and uncertainties. Curr. Med. Chem. 11 (15 1965 1982.
35. Weinreb O., Amit T., Bar-Am O., Sagi Y., Mandel S. Youdim M. B. (2006) Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl. 70, 457 465.
36. West M. J., Slomianka L. Gundersen H. J. (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231 (4 482 497.
37. West B. D., Shughrue P. J., Vanko A. E., Ransom R. W. Kinney G. G. (2006) Amphetamine-induced locomotor activity is reduced in mice following MPTP treatment but not following selegiline/MPTP treatment. Pharmacol. Biochem. Behav. 84 (1 158 161.
38. Youdim M. B. Bakhle Y. S. (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 147 (Suppl. 1 S287 S296.
39. Youdim M. B. Tipton K. F. (2002) Rat striatal monoamine oxidase-B inhibition by L-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease. Parkinsonism Relat Disord. 8 (4 247 253.
40. Youdim M. B., Wadia A., Tatton W. Weinstock M. (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. NY Acad. Sci. 939, 450 458.
41. Youdim M. B., Maruyama W. Naoi M. (2002) Neuroprotective action of rasagiline is dependent of rasagiline is dependent on activation of Bcl-2, PKC and proteasome complex and inhibition of mitochondrial permeability transition (PT). Neural Plast. 9 (2 125 126.
42. Youdim M. B., Amit T., Falach-Yogev M., Am O. B., Maruyama W. Naoi M. (2003) The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem. Pharmacol. 66 (8 1635 1641.
43. Youdim M. B., Maruyama W. Naoi M. (2005) Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc.) 41, 369 391.
44. Zecca L., Youdim M. B., Riederer P., Connor J. R. Crichton R. R. (2004) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5 (11 863 873.
45. Zhang X., Xie W., Qu S., Pan T., Wang X. Le W. (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem. Biophys. Res. Commun. 333 (2 544 549.
46. Zhu W., Wenjie Xie, Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M. B. Le W. (2007) Novel brain permeable iron chelators prevent lactacystin induced ubiquitin-proteasome inhibition and degeneration of nigrostriatal dopamine neurons. FESAB J. 21 (14 3835 3844.